| Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. | prostate, |
| The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer. | ovarian, |
| Genetic inhibition of TMPRSS2-ERG junction oncogene in prostate cancer by means of siRNA has strong antineoplastic effect in a mouse model and in vitro. | prostate, |
| Binding of fusion oncogene protein TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. | prostate, |
| results show chromatin looping by enhancers E1 and E2 with the promoters for PRCAT38 and TMPRSS2, indicating the co-regulation of PRCAT38 and TMPRSS2 by the same enhancers; findings demonstrate the utilization of shared enhancers in the joint regulation of two oncogenes in prostate cancer cells | prostate, |
| characterization of native ERG and Tmprss2:ERG variants reveals that their different oncogenic potential is affected by the status of the Ets domain and the configuration of the 5_ UTR region | None |
| Authors demonstrate a novel role for BRD4 in the formation of oncogenic TMPRSS2-ERG fusions via its involvement in the NHEJ DNA repair pathway. | None |